(Q48714177)

14 February 2018

title

Adult patients with Prader-Willi syndrome: clinical characteristics, life circumstances and growth hormone secretion. (English)

1 reference

14 February 2018

main subject

Prader–Willi syndrome

1 reference

Partsch CJ

1

1 reference

14 February 2018

Lämmer C

series ordinal

2

1 reference

14 February 2018

Gillessen-Kaesbach G

series ordinal

3

1 reference

14 February 2018

Pankau R

series ordinal

4

1 reference

14 February 2018

publication date

1 April 2000

1 reference

14 February 2018

Growth Hormone & I G F Research

published in

1 reference

14 February 2018

volume

10 Suppl B

1 reference

14 February 2018

page(s)

S81-5

1 reference

14 February 2018

Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Growth hormone secretion in Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Variability of growth hormone response to pharmacological and sleep tests performed twice in short children.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Comparison of the intravenous insulin and oral clonidine tolerance tests for growth hormone secretion. The Health Services Human Growth Hormone Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Comparison between Insulin-Induced Hypoglycemia and Growth Hormone (GH)-Releasing Hormone + Arginine as Provocative Tests for the Diagnosis of GH Deficiency in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Diagnosis of growth-hormone deficiency in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

New approach to the diagnosis of growth hormone deficiency in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Endocrine aspects of obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Linear growth response to exogenous growth hormone in Prader-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2800%2980015-5

7 January 2021

10.1016/S1096-6374(00)80015-5

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

10984259

1 reference

14 February 2018